Logo

GenPath Women's Health ClariTest

Mar 07, 2017

GenPath Women's Health, a business unit of BioReference Laboratories, is offering ClariTest, a noninvasive prenatal test that will be initially performed at Illumina. The test leverages massively parallel sequencing technology to screen for trisomies 13, 18, and 21, and sex chromosome abnormalities. It also offers the option to screen for five microdeletions, including 22q11.2, or DiGeorge syndrome. The company said that it will ultimately develop and validate its own laboratory-developed NIPT using Illumina technology.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.